Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. The company's mission is to boost the creation of new therapies for human diseases by reducing the complexity of biomedical big data into plausible solutions. Envisagenics focuses on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors and more remain to be discovered.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/28/17 | $2,250,000 | Seed |
Dynamk Capital | undisclosed |
| 09/29/21 | undisclosed | Series A |
Dynamk Capital M12 Madrona Venture Group New York Ventures Red Cell Partners Third Kind Venture Capital | undisclosed |
| 06/05/24 | undisclosed | Series B |
Bristol Myers Squibb Empire State Development Fund Red Cell Partners Third Kind Venture Capital | undisclosed |
